Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial | | 2022 |
Advanced age portends poorer prognosis after radical prostatectomy: a single center experience | | |
Factors influencing survival in metastatic castration resistant prostate cancer therapy | | |
Stereotactic radiotherapy of nodal oligometastases from prostate cancer: a prisma-compliant systematic review | | |
Role of baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment | | |
Immediate Versus Salvage Postoperative Radiotherapy in High-Risk Prostate Cancer Patients: A Critical Review | | 2022 |
Safety and Efficacy of Carbon-Ion Radiotherapy for Elderly Patients with High-Risk Prostate Cancer | | 2022 |
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer | | |
Assessment of Second Primary Cancer Risk Among Men Receiving Primary Radiotherapy vs Surgery for the Treatment of Prostate Cancer | | 2022 |
Systemic Treatments and Related Side Effects in Prostate Cancer | | 2022 |
Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer | Scientific Reports | 2022 |
The Impact of Gleason Grade 3 as a Predictive Factor for Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group) | Medicina (Lithuania) | 2022 |
Radical prostatectomy for patients with high-risk, very-high risk, or radiographic suspicion for metastatic prostate cancer: Perioperative and early oncologic results from the MUSIC statewide collaborative | Urologic Oncology: Seminars and Original Investigations | 2022 |
Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer | Prostate Cancer and Prostatic Diseases | |
2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial | Acta Oncológica | |
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends | Clinical Drug Investigation | |
Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer | Cancers | 2022 |
Prostate specif c antigen density as a prognostic factor in patients with prostate cancer treated with combined hormonal radiation therapy | Siberian Journal of Oncology | 2022 |
Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration‐resistant prostate cancer | Prostate | |
More Unacceptable Denials: Now It’s PSMA-Targeted PET/CT Imaging | Journal of Nuclear Medicine | 2022 |
PET-CT in Clinical Adult Oncology—IV. Gynecologic and Genitourinary Malignancies | Cancers | 2022 |
The Latest Data Specifically Focused on Long-Term Oncologic Prognostication for Very Old Adults with Acute Vulnerable Localized Prostate Cancer: A Nationwide Cohort Study | Journal of Clinical Medicine | 2022 |
Comparison of Estimated Late Toxicities between IMPT and IMRT Based on Multivariable NTCP Models for High-Risk Prostate Cancers Treated with Pelvic Nodal Radiation | International Journal of Particle Therapy | 2022 |
Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset | Urologic Oncology: Seminars and Original Investigations | 2022 |
A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report | BMC Medical Genomics | 2022 |
Role of Brachytherapy Boost in Clinically Localized Intermediate and High-Risk Prostate Cancer: Lack of Benefit in Patients with Very High-Risk Factors T3b–4 and/or Gleason 9–10 | Cancers | 2022 |
Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management | European Journal of Nuclear Medicine and Molecular Imaging | |
Clinical implications of homologous recombination repair mutations in prostate cancer | Prostate | 2022 |
Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy | Brachytherapy | 2022 |
Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer | Expert Review of Anticancer Therapy | |
Race‐specific prostate cancer outcomes in a cohort of low and favorable‐intermediate risk patients who underwent external beam radiation therapy from 1990 to 2017 | Cancer Medicine | |
Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer. | Current Oncology Reports | 2022 |
Recent results of HDR brachytherapy in the treatment of localized forms of prostate cancer | Ukrainian Journal of Radiology and Oncology | 2022 |
Lutetium Lu 177 Vipivotide Tetraxetan: First Approval. | Molecular Diagnosis and Therapy | 2022 |
Evolving trends in the management of low-risk prostate cancer | Clinical Genitourinary Cancer | 2022 |
Long-Term Medical Resource Consumption of Radical Prostatectomy vs. Intensity-Modulated Radiotherapy for Old Patients With Prostate Cancer: A Nationwide Population-Based Cohort Study. | Frontiers in Medicine | 2022 |
Quality of life after definitive linear accelerator-based stereotactic radiotherapy for prostate cancer: a longitudinal study. | Radiation Oncology | 2022 |
Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer. | BMC Cancer | 2022 |
Assessment of toxicity of elective pelvic lymph node irradiation in patients with high-risk prostate cancer | Onkologiya Zhurnal Imeni P A Gertsena | 2022 |
Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada. | Journal of Medical Economics | 2022 |
Table_1.docx | | 2020 |
Data_Sheet_1.ZIP | | 2020 |
DataSheet_1.docx | | 2020 |
Table_1.DOCX | | 2020 |
"Meta-analysis of elective pelvic nodal irradiation using moderate hypofractionation for high-risk prostate cancer" (MENHYP-ENI). | International Journal of Radiation Oncology Biology Physics | 2022 |
Delayed radical prostatectomy after a period of active surveillance is not associated with the use of secondary treatments compared with immediate prostatectomy | Prostate | 2021 |
Active surveillance inclusion criteria under scrutiny in magnetic resonance imaging-guided prostate biopsy: a multicenter cohort study. | Prostate Cancer and Prostatic Diseases | 2021 |
Prostate Cancer Treatment with Pencil Beam Proton Therapy Using Rectal Spacers sans Endorectal Balloons | International Journal of Particle Therapy | 2022 |
Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers. | Research and Reports in Urology | 2022 |
Long-Term Outcomes of a Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image-Guided Intensity-Modulated Radiotherapy for Localized High-Risk Prostate Adenocarcinoma | Advances in Radiation Oncology | 2022 |